The post Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns appeared on BitcoinEthereumNews.com. President Donald Trump (L), andThe post Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns appeared on BitcoinEthereumNews.com. President Donald Trump (L), and

Dimon says Trump debanking lawsuit ‘has no merit’ but he’s sympathetic to concerns

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

President Donald Trump (L), and JP Morgan CEO, Jamie Dimon.

Reuters

JPMorgan Chase CEO Jamie Dimon said Monday that while President Donald Trump’s lawsuit seeking $5 billion in damages for shuttering his accounts was without merit, he sympathized with the president’s anger over the episode.

Trump is accusing JPMorgan and others of closing his accounts for political reasons in what his conservative supporters have called discrimination.

“The case has no merit,” Dimon told CNBC’s Leslie Picker in an interview on the sidelines of a JPMorgan conference in Miami.

“But I agree with them,” he said. “They have the right to be angry. I’d be angry, too. Like, why is a bank allowed to do that?”

The answer, according to Dimon, is that banks are “forced” to debank individuals to comply with regulators who could punish companies for bringing reputational risk to a lender.

“We debank people because it causes legal, regulatory risk for us,” Dimon said. “It’s been much easier for a bank to say, ‘I’m not taking the risk, let them go bank elsewhere.'”

Trump sued Dimon and JPMorgan in January as part of a broader campaign begun after Trump regained office last year. The president, or his companies, has also sued Capital One over debanking claims; media outlets over alleged defamation; and even the IRS over the leak of his tax information.

In recent court filings, JPMorgan acknowledged it closed dozens of accounts associated with Trump in the weeks after the Jan. 6, 2021, Capitol attack.

While there isn’t an individual law stating that banks must drop customers over reputational risk, the industry operates under a framework of regulations and guidance that makes it risky for lenders to cater to certain clients.

The suit against JPMorgan, the world’s biggest bank by market cap, and its CEO puts Dimon in an awkward position.

It forces Dimon, one of the most outspoken leaders in finance, to toe the line between defending himself and his bank while not further angering Trump, who has the power to move markets with a social media post.

Further, the financial industry is just starting to benefit from a deregulatory push by Trump appointees that will enable banks to become more profitable and hold less capital for losses.

“There are a lot of misunderstandings here,” Dimon said. “Hopefully the law will change, and hopefully it’ll get sorted out.”

Source: https://www.cnbc.com/2026/03/02/dimon-trump-debanking-lawsuit-no-merit-concerns.html

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$3.085
$3.085$3.085
-1.43%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09